Other news to note
Wednesday, February 19, 2014
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said data showing that MM-141 is able to inhibit oncogenic signaling through the PI3K/AKT/mTOR pathway was published in Molecular Cancer Therapeutics.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.